Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world safety and discontinuation patterns of ibrutinib in B-cell malignancies: A 9-year experience from Qatar

View Full Paper
Ask AI
Bookmark
Share

Authors

GRGhasoub RolaAHAnas HamadRTRuba Y. Taha

Discussion

Loading...

Member takes

Overview

Retrospective cohort shows high adverse drug events and treatment discontinuation in B-cell patients using ibrutinib.

Key Points

  • To evaluate the safety, treatment discontinuation patterns, and adverse drug events associated with ibrutinib in B-cell malignancies.
  • Retrospective observational cohort study at the National Center for Cancer Care and Research in Qatar.
  • Patient records from those who initiated ibrutinib treatment between Jan 2016 and Dec 2024 were reviewed.
  • Data collected included demographics, ECOG status, comorbidities, treatment details, and adverse events.
  • Out of 65 patients, 76.9% were male with a median age of 62 years, and 45% experienced two or more toxicities.
  • The most common adverse events were cardiac (40.6%) and hypertension worsening (29%).
  • The median duration of treatment was 748 days, with 1-year cumulative incidence of toxicity at 76%.

Cite This Study

Rola et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d71chttps://doi.org/10.1182/blood-2025-7128
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 15PSQ-104 Real-world evidence: is ibrutinib as safe as evidence tells?2024 · 1 citations
  2. 25PSQ-038 Real-world safety of ibrutinib in clinical practice in patients with chronic lymphocytic leukaemia2024
  3. 3Long‐Term Clinical Outcomes, Adherence, Persistence, and Adverse Event Management in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib2026
  4. 4Incidence of cardiovascular and bleeding events and reasons for discontinuation in patients with chronic lymphocytic leukemia treated with ibrutinib—A retrospective analysis on consecutive patients from a well‐defined region2023 · 5 citations
  5. 5Cardiotoxicity in ibrutinib-treated patients: incidence, management, and impact on treatment outcomes2025